Healthy Subjects
Conditions
Brief summary
To assess the safety and tolerability of single, subcutaneous (SC) doses of BIIB059 in healthy Japanese subjects.
Interventions
DRUGBIIB059
Administered as specified in the treatment arm
DRUGPlacebo
Administered as specified in the treatment arm
Sponsors
Biogen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations * Must have been born in Japan, and both their biological parents and grandparents must have been of Japanese origin * Aged 18 to 55 years old, inclusive, at the time of informed consent, and must have a body mass index between 18 and 30 kilogram per square meter (kg/m2), and a body weight \>45 kg * All women of childbearing potential and all men must practice highly effective contraception during the study and for 16 weeks after their dose of study treatment
Exclusion criteria
* History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator * History or positive test result for human immunodeficiency virus. Current active hepatitis C virus infection (defined as hepatitis C virus RNA above the limit of detection). Positive test result for hepatitis B virus (defined as positive for hepatitis B surface antigen or hepatitis B core antibody). Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1 * Clinically significant abnormal laboratory test values, as determined by the Investigator, at Screening or Day -1 * Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 5 half-lives prior to Day -1 * History of alcohol or substance abuse (as determined by the Investigator), a positive urine drug or alcohol test at Screening or Day -1, an unwillingness to refrain from illicit or recreational drugs, or an unwillingness to abide by the alcohol restrictions NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 20 weeks | An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose: results in death; life-threatening event; requires inpatient hospitalization; significant disability; congenital anomaly; medically important event. |
| Percentage of Participants With Clinically Significant Abnormal Clinical Laboratory Parameters, Vital Signs, 12-Lead Electrocardiograms (ECG), and Physical Examination Findings | Up to 20 weeks | — |
| Percentage of Participants With Anti-BIIB059 Antibodies | Up to 20 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf), | Up to 112 days |
| Time to Reach Maximum Observed Concentration (Tmax) | Up to 112 days |
| Terminal Half-Life (t1/2) | Up to 112 days |
| Area Under the Concentration-Time Curve From Time 0 to 28 Days Post-dose (AUC0-28d) | Up to 28 days |
| Apparent Total Clearance (CL/F) | Up to 112 days |
| Apparent Volume of Distribution (Vz/F) | Up to 112 days |
| Time of Last Measurable Concentration (Tlast) | Up to 112 days |
| Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast) | Up to 112 days |
| Maximum Observed Concentration (Cmax) | Up to 112 days |
Countries
United States
Outcome results
None listed